Colchicine may not be effective in COVID-19 infection; it may even be harmful?
作者信息
Cumhur Cure Medine, Kucuk Adem, Cure Erkan
机构信息
Department of Biochemistry, Private Practice, Istanbul, Turkey.
Department of Rheumatology, Necmettin Erbakan University, Konya, Turkey.
出版信息
Clin Rheumatol. 2020 Jul;39(7):2101-2102. doi: 10.1007/s10067-020-05144-x. Epub 2020 May 11.
Abstract
摘要
相似文献
1
Colchicine may not be effective in COVID-19 infection; it may even be harmful?秋水仙碱可能对新型冠状病毒肺炎感染无效；甚至可能有害？
Clin Rheumatol. 2020 Jul;39(7):2101-2102. doi: 10.1007/s10067-020-05144-x. Epub 2020 May 11.
2
Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?秋水仙碱作为COVID-19的一种强效抗炎治疗方法：我们能让老狗学新把戏吗？
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):255. doi: 10.1093/ehjcvp/pvaa033.
3
Immune-Mediated Coagulopathy in COVID-19 Infection.新型冠状病毒肺炎感染中的免疫介导性凝血病
Semin Thromb Hemost. 2020 Oct;46(7):838-840. doi: 10.1055/s-0040-1714272. Epub 2020 Sep 2.
4
Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).氨苯砜、秋水仙碱和奥氮平作为辅助治疗药物预防新型冠状病毒肺炎相关的成人呼吸窘迫综合征（ARDS）。
Med Hypotheses. 2020 Aug;141:109774. doi: 10.1016/j.mehy.2020.109774. Epub 2020 Apr 23.
5
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.秋水仙碱治疗与 COVID-19 肺炎和急性呼吸窘迫综合征住院成年患者生存改善的相关性：单中心队列研究。
Ann Rheum Dis. 2020 Oct;79(10):1286-1289. doi: 10.1136/annrheumdis-2020-217712. Epub 2020 Jul 30.
6
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?芦可替尼对有急性呼吸窘迫综合征（ARDS）风险的新型冠状病毒肺炎（COVID-19）感染患者是否有效？
Ann Hematol. 2020 Jul;99(7):1675-1676. doi: 10.1007/s00277-020-04067-6. Epub 2020 May 14.
7
Diabetes and severity of COVID-19: What is the link?糖尿病与 COVID-19 严重程度：二者有何关联？
Med Hypotheses. 2020 Oct;143:109923. doi: 10.1016/j.mehy.2020.109923. Epub 2020 May 30.
8
Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?用烯丙哌三嗪治疗低氧血症型新冠肺炎“急性呼吸窘迫综合征”患者：越早越好？
Anaesth Crit Care Pain Med. 2020 Aug;39(4):451-452. doi: 10.1016/j.accpm.2020.07.003. Epub 2020 Jul 9.
9
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.秋水仙碱对比标准治疗对 COVID-19 住院患者心脏和炎症生物标志物及临床结局的影响：GRECCO-19 随机临床试验。
JAMA Netw Open. 2020 Jun 1;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136.
10
Viral Coagulopathy in Patients With COVID-19: Treatment and Care.新型冠状病毒肺炎患者的凝血功能障碍：治疗与护理。
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936776. doi: 10.1177/1076029620936776.
引用本文的文献
1
[Colchicine, an old friend's perspectives for rheumatology in COVID-19: a scoping review].[秋水仙碱：老朋友对COVID-19中风湿病学的看法：一项范围综述]
Rev Colomb Reumatol. 2022 Jun;29:S35-S47. doi: 10.1016/j.rcreu.2021.02.002. Epub 2021 Mar 27.
2
Clinical course of Covid-19 in a cohort of patients with Behçet disease.白塞病患者队列中新冠病毒病的临床病程
Med Clin (Engl Ed). 2022 Sep 23;159(6):262-267. doi: 10.1016/j.medcle.2022.08.009. Epub 2022 Sep 19.
3
Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?新冠病毒肺炎中的遗传易感性与炎症抑制剂：我们目前的进展如何？
Biomedicines. 2022 Jan 24;10(2):242. doi: 10.3390/biomedicines10020242.
4
Antiviral effects of azithromycin: A narrative review.阿奇霉素的抗病毒作用：一篇叙述性综述。
Biomed Pharmacother. 2022 Mar;147:112682. doi: 10.1016/j.biopha.2022.112682. Epub 2022 Feb 4.
5
Colchicine Against SARS-CoV-2 Infection: What is the Evidence?秋水仙碱抗新型冠状病毒2感染：证据有哪些？
Rheumatol Ther. 2022 Apr;9(2):379-389. doi: 10.1007/s40744-022-00425-0. Epub 2022 Feb 2.
6
Clinical course of Covid-19 in a cohort of patients with Behçet disease.Behçet 病患者队列中 COVID-19 的临床病程。
Med Clin (Barc). 2022 Sep 23;159(6):262-267. doi: 10.1016/j.medcli.2021.11.009. Epub 2021 Dec 28.
7
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.COVID-19 治疗的免疫调节剂：可能的作用机制和免疫病理学特征。
Mol Cell Biochem. 2022 Mar;477(3):711-726. doi: 10.1007/s11010-021-04325-9. Epub 2022 Jan 11.
8
Drug-based therapeutic strategies for COVID-19-infected patients and their challenges.用于 COVID-19 感染患者的药物治疗策略及其面临的挑战。
Future Microbiol. 2021 Dec;16:1415-1451. doi: 10.2217/fmb-2021-0116. Epub 2021 Nov 23.
9
Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials.秋水仙碱治疗 COVID-19 的疗效和安全性：一项随机对照试验的荟萃分析。
RMD Open. 2021 Oct;7(3). doi: 10.1136/rmdopen-2021-001746.
10
SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.严重急性呼吸综合征冠状病毒 2 型、寨卡病毒和支原体：这些新发病毒性和细菌性传染病的结构、发病机制及一些治疗选择。
Biochim Biophys Acta Mol Basis Dis. 2021 Dec 1;1867(12):166264. doi: 10.1016/j.bbadis.2021.166264. Epub 2021 Sep 3.
本文引用的文献
1
Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis.达格列净对2019冠状病毒病感染有保护作用吗？一种假说。
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):405-406. doi: 10.1016/j.dsx.2020.04.024. Epub 2020 Apr 21.
2
Comment on "Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19".关于《血管紧张素转换酶2的器官保护作用及其对新型冠状病毒肺炎预后的影响》的评论
J Med Virol. 2020 Sep;92(9):1423-1424. doi: 10.1002/jmv.25848. Epub 2020 Jun 2.
3
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
4
Colchicine--Update on mechanisms of action and therapeutic uses.秋水仙碱——作用机制与治疗用途的最新进展
Semin Arthritis Rheum. 2015 Dec;45(3):341-50. doi: 10.1016/j.semarthrit.2015.06.013. Epub 2015 Jun 26.
5
Mechanism of action of colchicine in the treatment of gout.秋水仙碱治疗痛风的作用机制。
Clin Ther. 2014 Oct 1;36(10):1465-79. doi: 10.1016/j.clinthera.2014.07.017. Epub 2014 Aug 21.
6
The regulation of NHE₁ and NHE₃ activity by angiotensin II is mediated by the activation of the angiotensin II type I receptor/phospholipase C/calcium/calmodulin pathway in distal nephron cells.血管紧张素 II 通过激活远曲小管细胞中的血管紧张素 II 型 1 受体/磷脂酶 C/钙/钙调蛋白途径来调节 NHE₁ 和 NHE₃ 的活性。
Eur J Pharmacol. 2013 Dec 5;721(1-3):322-31. doi: 10.1016/j.ejphar.2013.08.043. Epub 2013 Sep 25.
7
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.人血管紧张素转换酶相关羧肽酶对生物肽的水解作用。
J Biol Chem. 2002 Apr 26;277(17):14838-43. doi: 10.1074/jbc.M200581200. Epub 2002 Jan 28.
8
Angiotensin II stimulates vesicular H+-ATPase in rat proximal tubular cells.血管紧张素II刺激大鼠近端肾小管细胞中的囊泡型H⁺-ATP酶。
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9665-8. doi: 10.1073/pnas.95.16.9665.
9
Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis.秋水仙碱的抗炎和抗纤维化特性：对特发性肺纤维化的意义。
Lung. 1997;175(1):41-51. doi: 10.1007/pl00007555.
10
Intracellular pH and the control of multidrug resistance.细胞内pH值与多药耐药性的控制
Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1128-32. doi: 10.1073/pnas.91.3.1128.
Zotero 插件